Timothy J. LaBua

Associate Attorney

Skadden, Arps, Slate, Meagher & Flom LLP

Associate Attorney

Wilmer Cutler Pickering Hale & Dorr LLP

• Investment & Operations Counsel at prominent value-focused hedge fund

• ARCH in its purchase of preferred equity in Myeloid Therapeutics, Inc.
• SURGE Therapeutics, Inc. in its Series B Financing
• ARCH in its purchase of preferred equity in Ultivue, Inc.
• GV, ARCH and DCVC in the purchase of preferred equity in Chroma Medicine, Inc.
• Epalex Corporation in its Series A-3 Financing
• 5AM Ventures in its purchase of preferred equity in Nido Biosciences, Inc.
• Vernal Biosciences, Inc. in its Series A Financing
• AllerFund Ventures in numerous purchases of preferred equity
• 5AM Ventures in its purchase of preferred equity in Latigo Biosciences, Inc.
• 5AM Ventures and MPM Capital in their purchase of preferred equity in Entrada Therapeutics, Inc.
• FOG Pharmaceuticals, Inc. in its Series C Financing
• GV in its purchase of preferred equity in Hyperfine Research, Inc.
• GV in its purchase of preferred equity in Adagio Therapeutics, Inc.
• Biofeedback Design, Inc. in its Series A Financing
• 5AM Ventures and RA Capital in the purchase of preferred equity in Vor Biopharma, Inc.
• GV in its purchase of Series A-2 Preferred Stock in Verve Therapeutics, Inc.
• Lysosomal Therapeutics, Inc. in the sale of certain assets to Bial-Biotech Investments, Inc.
• PIC Therapeutics, Inc. in its Series Seed Financing
• 5AM Ventures in its purchase of preferred equity in Scientist.com
• Kanyos Bio, Inc. in its acquisition by Anokion SA
• Massachusetts Eye and Ear in its subscription for equity in Affinia Therapeutics, Inc.
• 6Dimensions Capital in its purchase of preferred equity in Halda Therapeutics, Inc.
• Siamab Therapeutics, Inc. in its acquisition by a publicly listed acquiror
• HotSpot Therapeutics, Inc. in its acquisition of Macroceutics, Inc.
• 5AM Ventures in its purchase of preferred equity in VOR Biopharma
• Kantum Pharma, Inc. in its convertible debt offering
• 6Dimensions Capital in its purchase of preferred equity in HiberCell
• 5AM Ventures in its purchase of preferred equity in Nido Biosciences
• GV in its purchase of preferred equity in Verve Therapeutics, Inc.
• Apic Bio, Inc. in its Series A Financing
• XyloCor Therapeutics, Inc. in its Series A Financing
• Venn Biosciences Corporation in its Series A Financing
• Guardian Therapeutics, LLC in its acquisition of Band Therapeutics, LLC
• Synedgen, Inc. in its out-license of IP and sale of assets to Synspira, LLC
• Synspira, LLC in its equity/debt financing and research funding from The Cystic Fibrosis Foundation Trust
• FOG Pharmaceuticals, Inc. in its Series B Financing
• LifeMine Therapeutics, Inc. in its Series A Financing
• Renoviso, Inc. in its Series A-1 Financing
• Lundbeckfond Ventures in its sale of certain royalty rights
• Bio-Pharm, Inc. in its acquisition by Torrent Pharmaceuticals Ltd.
• Alnylam Pharmaceuticals, Inc. in its strategic collaboration with Vir Biotechnology to develop RNAi therapeutics for infectious diseases
• VivoPharm Pty. Ltd. in its acquisition by Cancer Genetics, Inc.
• GO Therapeutics, Inc. in its Series A-1 Financing
• Lysosomal Therapeutics, Inc. in its exclusive option arrangement with Allergan plc